52-Week Performance Chart

Powered by FactSet Research Systems Inc

Recent Company News

More

Powered by FactSet Research Systems Inc.

Corporate Actions/Books Closed

Go to Archived DR Corporate Actions

Capital Raising Events

More
DR Price Date DR Price (USD) US/Non-US/Total DRS US/Non-US/Total DR Capital Raised
Jul 19, 2023 490.00 1,917,715
0
1,917,715 		939,680,350
0
939,680,350
Mar 28, 2022 300.00 1,783,701
0
1,783,701 		535,110,300
0
535,110,300
Feb 03, 2021 320.00 2,076,750
0
2,076,750 		664,560,000
0
664,560,000
May 27, 2020 205.00 3,132,915
0
3,132,915 		642,247,575
0
642,247,575

No DR Events are available.

Data provided by Thomson Reuters

Institutional Ownership

More
TOP INSTITUTIONAL HOLDERS POSITION
Fidelity Management & Research Co. LLC 5,302,686
T. Rowe Price Associates, Inc. (IM) 4,703,181
Artisan Partners LP 3,069,995
TOP MUTUAL FUND HOLDERS POSITION
American Funds EuroPacific Growth Fund 1,164,588
Fidelity Growth Company Commingled Pool 875,886
T Rowe Price New Horizons Fund 779,726

Data provided by FactSet Research Systems Inc.

DR Details

DR Symbol ARGX
CUSIP 04016X101
DR Venue NASDAQ Stock Market
DR ISIN US04016X1019
Ratio DR:ORD 1:1
Underlying ISIN NL0010832176
Underlying SEDOL BNHKYX4
Country Netherlands
Effective Date May 23, 2017
Depositary BK (Sponsored)
Industry Pharma. & Biotech.
Books Open/Closed Open
argenx is a clinical-stage biotechnology company developing differentiated therapies for the treatment of severe autoimmune diseases and cancer. The Company is developing its main product candidate, efgartigimod, for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris and chronic demyelinating polyneuropathy, all of which are severe autoimmune diseases associated with high levels of circulating pathogenic immunoglobulin G antibodies for which there are few biologic treatments and a severe unmet medical need exists. The Company is also developing cusatuzumab in hematological cancer indications, acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS Deposit Agreement
Annual Depositary Service up to $0.0500
Cancellation up to $0.0500
Cash Distribution up to $0.0500
Issuance up to $0.0500
Registrar Inspection up to $0.0000
Cash Distribution(Other) up to $0.0500
Rights - Issuance up to $0.0500
Stock Dividend up to $0.0500
Transfer up to $0.0000
Cable Fee per Cancellation $17.5000

Monthly Trading Summary

More
Month Month End DR Close Price DR Trading Volume Avg Day DR Trading Volume
Apr.25 645.14 9,138,067 435,146
Mar.25 591.87 6,763,010 322,048
Feb.25 624.67 5,083,328 267,544

Powered by FactSet Research Systems Inc.

This information and data is provided for general informational purposes only.  Certain displayed prices may not reflect direct quotes from any market or exchange, but may instead reflect an approximation of price based on a methodology that includes a calculation that includes the price of underlying securities and foreign exchange rate selected for such purpose. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to Terms of Use

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

Data provided by Thomson Reuters, Inc.

BNY.COM TERMS OF USE PRIVACY POLICY

© 2025 The Bank of New York Mellon Corporation. Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Quotes delayed at least 15 minutes. Market data provided by ICE Data Services. ICE Limitations.
News provided by Comtex News Network and MarketWatch. Powered and implemented by FactSet. Legal Statement.

Certain information included in this website is proprietary to Mergent, Inc. (Mergent) Copyright © 2003-2025. Reproduction of such information in any form is prohibited. Because of the possibility of human or mechanical error by Mergent's sources, Mergent or others, Mergent does not guarantee the accuracy, adequacy, completeness, timeliness or availability or for the results obtained from the use of such information. Mergent Terms of Use apply

Holdings information provided by FactSet Research Systems Inc. Copyright © 2003-2025 FactSet Research Systems Inc. All rights reserved.

Thomson Reuters Marks: The THOMSON REUTERS Kinesis Logo depicted below and THOMSON REUTERS

Redistributor shall display or print the Thomson Reuters Trademarks when Redistributor's Customers are given access to the Services.

Where Redistributor makes available on display any and all Thomson Reuters Marks attributable to the Services, Redistributor shall include the following language in the Help About section or in a general attribution page: "The THOMSON REUTERS Kinesis Logo and THOMSON REUTERS are trademarks of Thomson Reuters and its affiliated companies in the United States and other countries and used herein under license."

Additional Attribution Guidelines by Thomson Reuters: Redistributor shall display or print the following notice in the Help About section or in a general attribution page. "Copyright ©, Thomson Reuters, 1999-2025. All Rights Reserved. Use, duplication, or sale of this service, or data contained herein, except as described in the [Authorized Products name] Subscription Agreement, is strictly prohibited."

THOMSON REUTERS